Advances in the treatment of graft-versus-host disease

被引：9

作者：

Vogelsang, GB ^{[1
]}

机构：

[1] Johns Hopkins Univ, Baltimore, MD 21287 USA

来源：

LEUKEMIA | 2000年 / 14卷 / 03期

关键词：

GVHD; conditioning; treatment;

D O I：

10.1038/sj.leu.2401687

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Graft-versus-host disease (GVHD) is a complicated disease whose treatment requires an equally multifaceted approach. Recipient conditioning, donor T cell activation, and end stage effecters all may be potential targets for treatment. Many drugs used in the past are returning to the forefront for investigation. Some of the newer nucleoside analogs that are in various stages of development, such as fludarabine and pentostatin, are showing promising activity in GVHD.

引用

收藏

页码：509 / 510

页数：2

相关论文

共 6 条

[1]

ANASETTI C, 1994, BLOOD, V84, P1320

[2] Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation [J].

Hill, GR ;

Cooke, KR ;

Teshima, T ;

Crawford, JM ;

Keith, JC ;

Brinson, YS ;

Bungard, D ;

Ferrara, JLM .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :115-123

[3]

Or R, 1997, BLOOD, V90, P471

[4] Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies [J].

Porter, DL ;

Connors, JM ;

Van Deerlin, VMD ;

Duffy, KM ;

McGarigle, C ;

Saidman, SL ;

Leonard, DGB ;

Antin, JH .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1234-1243

[5] A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo [J].

Schlegel, PG ;

Aharoni, R ;

Chen, YF ;

Chen, J ;

Teitelbaum, D ;

Arnon, R ;

Sela, M ;

Chao, NJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (10) :5061-5066

[6] Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].

Slavin, S ;

Nagler, A ;

Naparstek, E ;

Kapelushnik, Y ;

Aker, M ;

Cividalli, G ;

Varadi, G ;

Kirschbaum, M ;

Ackerstein, A ;

Samuel, S ;

Amar, A ;

Brautbar, C ;

Ben-Tal, O ;

Eldor, A ;

Or, R .

BLOOD, 1998, 91 (03) :756-763